Frontline Pembrolizumab/Axitinib Approved in Japan for Advanced RCC

December 20, 2019 – Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma (RCC). The approval is based on results from the phase III KEYNOTE-426 trial, in which pembrolizumab combined with axitinib demonstrated statistically significant improvements in both progression- … (leggi tutto)